Skip to main navigation
Iovance Biotherapeutics
  • News
  • Investors
  • Email Alerts
  • Patients
  • Join Us
  • Contact Us
  • Site Map
  • Contact Us
  • Twitter
  • LinkedIn
 
 
  • Home
  • Our Company
    • About Iovance Biotherapeutics
    • Management
    • Board of Directors
    • Research Partners & Collaborators
  • Our Products
  • Our Science
    • About TIL
    • Our T-cell Therapy Platforms
    • Scientific Publications & Presentations
    • Next Generation Research
  • Our Technology
    • Iovance Cell
      Therapy Center
    • Manufacturing
    • Intellectual Property
  • Our Pipeline
    • Clinical Pipeline
    • Clinical Trials
    • Expanded Access Policy
  • Careers
    • Current Opportunities
    • Our Culture
  • News
  • Investors
  • Email Alerts
  • Patients
  • Join Us
  • Contact Us
  • Site Map
  • Contact Us
  • Twitter
  • LinkedIn

Event Details

  • Overview
  • News & Events
    • Press Releases
    • Events & Presentations
  • Stock Information
    • Stock Quote & Chart
    • Historical Price Lookup
    • Ownership Summary
    • Analyst Coverage
  • Financial Information
    • SEC Filings
    • Financial Reports
    • Quarterly Results
    • Earnings Estimates
  • Fundamentals
    • Snapshot
    • Trading Statistics
    • Balance Sheet
    • Income Statement
    • Cash Flow
    • Ratios
  • Corporate Governance
    • Governance Highlights
    • Committee Composition
Investor Toolkit
  • Print Page
  • RSS
  • Email Alerts
Feb 16, 2024 at 4:15 PM EST

AMTAGVI FDA Approval

Click here for webcast

Supporting Materials

AMTAGVI USPI 327.8 KB
Iovance Biotherapeutics
  • News
  • Investors
  • Email Alerts
  • Patients
  • Join Us
  • Contact Us
  • Site Map
  • Contact Us
  • Twitter
  • LinkedIn
© 2024 IOVANCE Biotherapeutics, Inc. All Rights Reserved. IOVANCE logo is a trademark owned
by IOVANCE Biotherapeutics, Inc.
  • Privacy Notice
  • Terms of Use